Showing 1971-1980 of 3225 results for "".
Pruritus In PN and AD: Challenge How You Manage Itch
https://practicaldermatology.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://practicaldermatology.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://practicaldermatology.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://practicaldermatology.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://practicaldermatology.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://practicaldermatology.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.